The Taylor Star-STEM,Business and Political Science: December 2019

Monday, December 30, 2019

Chinese Carmaker Nio Shows Improvement

Electric carmaker Nio of Shanghai, China showed improved third quarter performance, beating the consensus estimate.Deliveries were up 35%;sales rose 22.5 %;and total revenue gained 25%, rising to 257 million dollars, versus the estimate of 234 million.*
Nio designs,manufactures and sells smart,connected vehicles that integrate with next gen technologies and artificial intelligence.Its ES 8 SUV can accelerate to 100 km/hr in 4.4 seconds and has a range of up to 500 km on a single charge.Nio also offers vehicle charging systems such as Power Home and Power Swap.*
Nio's market cap is four billion.It doesn't pay a dividend.Year on year, its shares are down 39.41%.It has been called "the Tesla of China".
At close of NYSE trading today,Nio stock was up 1.38 to 3.80,or 57.02%.*
Nio,Inc (NIO)

Thursday, December 26, 2019

Monday, December 9, 2019

Growing Kilauea Volcano Crater Lake Update (Dec. 3, 2019)

Boeing – Commercial Crew Program Launch Update

Boeing – Commercial Crew Program

Merck Expands Oncology Portfolio

On 9 December 2019,New Jersey-based pharma titan Merck announced it is acquiring biopharmaceutical prospect ArCule,Inc. for 20 dollars a share,or about 2.7 billion dollars.ArCule's lead investigational candidate,ARQ 531,is an oral medication in a phase 2 dose expansion study for the treatment of B-cell malignancies (leukemia).
ARQ 531 is a highly selective, reversible inhibitor that,in early clinical trials, demonstrated a manageable safety profile and early signs of anti-tumour activity for the treatment of patients with relapsed or refactory chronic lymphocytic leukemia (CLL) and Richter's Transformation.*
ArQule CEO Paolo Pucci said:
With this agreement,ArQule's pipeline will benefit from Merck's vast capabilities and determined engagement to benefit the patients who we have always strived to serve.*
ArQule's discovery efforts are focused on the identification and development of novel kinase inhibitors, the company noted.iAll four of its drug candidates are in targeted, biomarker-defined patient populations.*
Merck&Co Inc (MRK), ArQule Inc (ARQC)